Please assess the completion status of the following clinical trial:

Trial Title: Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pts have histologically confirmed diagnosis of recurrent/progressive WHO gr III \& IV MG \& meet following inclusion criteria:~* Age \>18 yrs~* Interval of \>4 wks since prior surgery~* Interval of \>4 wks since prior external beam radiation therapy (XRT) or chemo, unless there is unequivocal evidence of progressive disease \& pts have recovered from all anticipated toxicity of most recent therapy~* Karnofsky performance status score \>60~* Hematocrit \> 29 percent, absolute neutrophil count (ANC) \>1,500 cells/microliter, platelets \>100,000 cells/microliter~* Serum creatinine \<.5mg/dl, blood urea nitrogen (BUN) \<25 mg/dl, serum glutamate oxaloacetate transaminase (SGOT) \& bilirubin \<1.5 x upper limit of normal (ULN)~* For pts on corticosteroids, they have been on stable dose for 1 wk prior to entry~* Pts have had prior bevacizumab are eligible however interval of \>6 wks must have elapsed since their last dose~* Signed informed consent approved by Institutional Review Board (IRB) prior to patient entry;~* If sexually active, pts must agree to take contraceptive measures for duration of treatments~Exclusion Criteria:~* Prior therapy w either bevacizumab/EGFR-directed agents~* \>3 prior recurrences~* Pregnancy/breast feeding~* Co-medication w immuno-suppressive agents other than corticosteroids including but not limited to cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil~* Evidence of central nervous system (CNS) hemorrhage on baseline MRI on CT scan~* Pts who require therapeutic anti-coagulation~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring IV antibiotics \& psychiatric illness/social situations that would limit compliance w study requirements, or disorders associated w significant immunocompromised state~* Pts w another primary malignancy that has required treatment within past year~* Pts w acute/chronic renal insufficiency/those w acute renal insufficiency of any severity due to hepato-renal syndrome/in peri-operative liver transplantation period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bevacizumab + Erlotinib (Type: EXPERIMENTAL): Bevacizumab + Erlotinib

Based on this trial design, predict the completion outcome and termination type (if applicable).